ALS standard of care consensus

Neurology

Volumn 48, Issue 4 SUPPL. 4, 1997, Pages

  Miller, Robert G ^a   Sufit, Robert ^b   Mitsumoto, Hiroshi ^c   Gelinas, Deborah F ^d   Brooks, Benjamin Rix ^e  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Forbes Norris ALS Research Center   (United States)

^e University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL FEATURE; CONFERENCE PAPER; DECISION MAKING; DEGENERATIVE DISEASE; DOCTOR PATIENT RELATION; ELECTROMYOGRAM; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0030940577     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.4_suppl_4.33s     Document Type: Conference Paper

References (5)

1. Lee RJJ, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207-215.
2. Mitsumoto H. Classification and clinical features of amyotrophic lateral sclerosis. In: Mitsumoto H, Norris FH, eds. Amyotrophic lateral sclerosis: a comprehensive guide to management. New York: Demos Publications, 1994:1-19.
3. World Federation of Neurology Research Group on Neuromuscular Diseases. El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. J Neurol Sci 1994;124(suppl):96-107.
4. Bensimon G, Lacomblez L, Meininger V, and the ALS/riluzole study group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
5. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.